<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156036">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068470</url>
  </required_header>
  <id_info>
    <org_study_id>59210</org_study_id>
    <nct_id>NCT01068470</nct_id>
  </id_info>
  <brief_title>Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy</brief_title>
  <acronym>LAK</acronym>
  <official_title>Lymphokine Activated Killer (LAK) Cell Activity Against Cell Lines In-vitro of LAK Generated in Vivo by Pulse Interleukin-2 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated
      Killer cells (LAK). This study will determine if these killer cells are able to kill certain
      standard cell-lines in the laboratory.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples will be taken from patients undergoing outpatient Interleukin-2 therapy to
      measure the LAK cytotoxicity at baseline, after 1 cycle of therapy and 2 months later. The
      LAK cytotoxicity assay will be a standard colorimetric assay that measures lactic
      dehydrogenase release from lysed cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left the institution
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>LAK cytotoxicity</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Melanoma</condition>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>patients with melanoma or kidney cancer</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing Interleukin-2 therapy under the care of physicians at Loma Linda
        University Cancer Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be undergoing Interleukin-2 therapy under the care of physicians at
             Loma Linda University Cancer Center

          -  Patients must sign and give written informed consent in accordance with institutional
             and federal guidelines

        Exclusion Criteria:

          -  Patients not undergoing Interleukin-2 therapy under the care of physicians at Loma
             Linda University Cancer Center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Quan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>California</state>
        <zip>92223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-2</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Lymphokine Activated Killer cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
